The FDA expands nogapendekin alfa inbakicept in bladder cancer, European regulators back daraxonrasib in pancreatic cancer, and more.
Related to this article
The FDA set a PDUFA target action date of March 31, 2027, for tabelecleucel in relapsed or refractory EBV-positive posttransplant lymphoproliferative disease.
Advertisement
Advertisement
Trending on OncLive
1
Lisaftoclax Plus Acalabrutinib Received Breakthrough Therapy Designation in China for Treatment-Naive CLL/SLL
2
Tolerability Remains a TROP2-Directed ADC Hurdle in EGFR-Mutated NSCLC
3
Pembrolizumab Plus Enfortumab Vedotin Earns EC Approval in Resectable MIBC
4
Dr Sinicrope on CRC Abstracts to Watch at the 2026 ESMO Congress
5